China
Africa
Explore chapters and articles related to this topic
Fetal Heart Rate Variability
Published in Herbert F. Jelinek, David J. Cornforth, Ahsan H. Khandoker, ECG Time Series Variability Analysis, 2017
Faezeh Marzbanrad, Yoshitaka Kimura, Marimuthu Palaniswami, Ahsan H. Khandoker
Obtaining noninvasive fECG through the maternal abdomen has been a vast and challenging area of research in engineering and clinical technology over the last decade [36, 37, 38, 39]. Noninvasive fECG can be used during pregnancy as early as the 18th week of gestation, while invasive fECG via scalp requires data collection using intrauterine electrodes with direct contact to fetal skin, which requires uterine rupture and generally can be only used during labor [40, 41].
Profile of the Jada® System: the vacuum-induced hemorrhage control device for treating abnormal postpartum uterine bleeding and postpartum hemorrhage
Published in Expert Review of Medical Devices, 2021
Mary D’Alton, Kara Rood, Hyagriv Simhan, Dena Goffman
The Jada System is appropriate to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage attributable to uterine atony when conservative management is warranted. The Jada System should not be used with the following conditions: ongoing intrauterine pregnancy, untreated uterine rupture, unresolved uterine inversion, current cervical cancer, known uterine anomaly, or current purulent infection of the vagina, cervix, or uterus. Additionally, use should be avoided in patients where the cervix is unable to be dilated to 3 cm, since that minimum dilation is required for safe placement of the intrauterine device. The Jada System has not been evaluated for safety and effectiveness in uteri less than 34 gestational weeks in size, with placenta accreta, or in patients with a diagnosis of coagulopathy. In the setting of obstetric hemorrhage, treatment with the Jada System is not a substitute for aggressive resuscitation, blood transfusion or escalation to surgical management when indicated. When there is a concern for clinical deterioration or ongoing bleeding, prompt reassessment, and more aggressive treatments may be indicated.